Browse all clinical evidence, news, and expert commentary
Recurrent UTI drives a large share of antibiotic use in women. The alternatives vary a lot in how much evidence backs them.
This week, our expert insights will guide you through a case study from Jan Brassington’s webinar, ‘Managing Pain in Palliative Care.’ You can now watch it as an on-demand video on our CPD Webinars page!
Medicine Central | Clinical Update. Safety warnings from MHRA on the use of 5-alpha reductase inhibitors, sometimes referred to as DHT blockers.
What UK primary care needs to understand about the grey market peptide trade
The SCOUT trial is the first pragmatic head-to-head comparison of all four commonly used UTI regimens in a single trial. The results reinforce rather than redraw the UK prescribing picture — but they do sharpen one key question for primary care.
The mandate is clear: if a diagnosis remains unsubstantiated or symptoms escalate after three appointments — Reflect, Review, and Rethink. Three strikes and we rethink.
The PRUDENCE trial tested point-of-care diagnostics across 2,639 patients in 13 countries. It didn't reduce antibiotic prescribing. The reason why matters more than the result.
Prescribing gabapentinoids, benzos and Z-drugs? The ending comes first now.
